Abstract 4328
Background
The treatment of cancer has improved and many of the patients’ will return to work. Cancer treatments can have significant impact on work- and functional abilities creating challenges for return to work. Occupational health care services have an important role in supporting patients’ Return-to-Work-process. The purpose of the study was to a) explore cancer patients experiences on support received from occupational health services and b) explore how the services need to be developed.
Methods
Qualitative approach with thematic interview as data collection method was used to explore breast cancer patientś experiences (N = 8). The data was analysed by using thematic content analysis. Five of the cancer patients interviewed had already returned to work after cancer treatments and three were returning work in short period of time.
Results
The main challenges cancer patients confronted formed four categories; factors related to work, workplace, cancer and treatment types and to individual factors. The experienced support by occupational health services varied. The requirement to assess ability to work in the time of 90 sickness days was filled and planning the return-to-work in collaboration between occupational health care, cancer patient and employer occurred in most cases. However, otherwise, the role was passive and patients wished to have more contact with professionals working in the occupational health services.
Conclusions
Previous research highlights the need of collaboration between cancer patients and occupational health care services. Based on the study results, this collaboration needs to be enhanced. Occupational health care providers need to co-ordinate more actively the return-to-work -processes even the special health care is responsible for cancer treatments. From individual perspective, information, psychosocial support and regular evaluation of ability to work are forms of services cancer patient need from the occupational services for successful Return-to-Work. Results of this study can be used to developing occupational health services in national and international context.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Turku University of Applied Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract